Building Resilient Biotech Teams in Cell and Gene Therapy with Nelly Viseux
About this episode
Nelly Viseux discusses building resilient biotech teams in cell and gene therapy, emphasizing adaptability and effective risk management.
How do you build an organization that can absorb change, learn from failure, and keep patients at the center—even when the science is uncertain? Nelly Viseux shares lessons from over 20 years in biotech and a decade leading cell and gene therapy development. Nelly discusses how she structured a 100-person CMC organization at Regeneron to balance innovation with operational execution, why documenting your assumptions is critical to managing risk, and what it really takes to maintain resilience when you're literally holding patient lives in your hands. A few of Nelly's key takeaways: Resilience is adaptability —build organizations that absorb and anticipate change rather than resist it Separate innovation from execution with intentional gates for when new approaches are ready to implement Document your assumptions so you can revisit decisions effectively when circumstances change Failure is a process problem, not a personal one —root cause analysis should improve systems, not assign blame Data is the common language that aligns scientists, regulators, and stakeholders Everyone is a leader in cell therapy—manufacturing and QC teams hold patient lives in their hands About Nelly…
More episodes of The Life Science Rundown
- TerSera's VP of Quality on the Audit Risk Hiding Inside Your Own Procedures
- Why Kidney Disease Innovation Is a Tale of Two Cities — and What It Would Take to Change That
- Syncing Global Regulatory Filings Across FDA, EMA, and PMDA with AJ Acker
- Navigating Regulatory Leadership Across Large and Small Life Science with Tammy Sarnelli
- Getting Data Governance for Regulatory Submissions Right Before AI Gets it Wrong with Cary Smithson
- Building Phase-Appropriate Quality from Preclinical to Commercial with Jackie Klecker
Explore listener stats, chart rankings, contacts and more on the The Life Science Rundown podcast page.